Medicamen Biotech Limited

NSE: MEDICAMEQ · Unclassified

₹275.70+4.99%06 Nov 2026

Ask the data

Instant answers about Medicamen Biotech Limited — computed from its filings, no language model

Market cap₹374 cr

Current price₹275.70

High / Low₹416 / ₹220

P/E34.5

P/B1.36

Book value₹203.2

ROE3.9%

ROCE4.8%

Debt / equity0.17

Dividend yield0.36%

EPS (TTM)₹7.99

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY22	FY23	FY24	FY26
Revenue	115.5	140.9	179.3	197.8
EBITDA	23.6	23.9	22.2	19.6
Operating margin	20.4%	16.9%	12.4%	9.9%
Interest	1.4	2.9	4.4	3.5
Depreciation	5.8	6.4	7.1	7.2
Profit before tax	18.1	17.1	13.1	12.0
Tax	3.2	2.3	3.6	2.2
Net profit	0.0	14.8	10.9	9.6
EPS ₹	12.19	11.82	7.50	7.22
Operating cash flow	4.1	-6.3	-0.4	-33.2
Capex	8.6	6.6	6.3	4.8
Dividend paid	1.2	1.3	1.3	1.4
Total assets	—	278.5	294.5	372.0
Equity	—	193.4	200.5	275.6

Quarterly performance

last 19 quarters · ₹ crore

showing latest 8 of 19 periods

	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Revenue	32.5	32.6	22.8	33.1	33.5	35.6	38.7	41.9	43.5	46.5	47.3	43.0	44.7	45.1	43.0	47.2	46.9	60.6	47.9
Operating profit	6.2	6.3	5.0	5.7	5.8	5.9	6.5	7.0	4.6	4.9	5.8	3.5	5.3	6.7	4.6	5.2	4.4	5.4	4.3
Operating margin	19.2%	19.3%	21.8%	17.1%	17.4%	16.5%	16.8%	16.6%	10.7%	10.5%	12.2%	8.0%	11.9%	14.9%	10.7%	10.9%	9.3%	9.0%	9.0%
Other income	0.5	0.8	0.3	1.0	0.5	0.6	0.3	0.4	0.6	0.8	0.6	0.6	0.3	0.1	0.5	0.4	0.5	1.7	0.9
Interest	0.3	0.5	0.6	0.8	0.6	0.7	0.9	1.0	0.9	0.7	1.9	0.7	1.0	0.8	1.1	1.0	1.0	0.4	0.8
Depreciation	1.4	1.6	1.5	1.5	1.6	1.6	1.6	1.7	1.8	1.8	1.8	1.8	2.6	2.2	1.8	1.9	1.8	1.7	1.8
Profit before tax	5.0	5.1	3.2	4.3	4.1	4.2	4.4	4.7	2.5	3.3	2.7	1.6	2.0	3.9	2.1	2.7	2.1	5.1	2.6
Tax	0.8	1.3	0.5	0.7	0.5	0.5	0.6	0.7	1.0	1.2	0.6	0.8	1.1	0.9	0.5	0.6	0.5	0.6	0.7
Net profit	4.2	3.8	0.0	3.6	3.6	3.8	3.9	4.0	1.5	0.0	2.1	1.4	1.5	2.9	2.1	2.7	2.2	3.9	2.1
EPS ₹	3.46	3.09	2.25	2.94	2.85	2.98	3.03	3.12	1.17	1.60	1.61	0.63	0.71	2.30	1.18	1.56	1.21	3.28	1.36
Revenue YoY	—	—	—	—	3.1%	9.0%	70.0%	26.7%	29.9%	30.7%	22.4%	2.6%	2.8%	-2.9%	-0.0%	5.4%	3.9%	—	11.3%
Profit YoY	—	—	—	—	-14.7%	-0.3%	—	10.0%	-58.1%	-100.0%	-45.2%	-65.8%	-3.3%	—	59.3%	82.9%	-25.0%	—	-1.4%

Earlier results (standalone, Sep '07 – Jun '21)

₹ crore · from BSE, before the NSE XBRL filings begin

Medicamen Biotech Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 13 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†	FY18†	FY19†	FY20†	FY21†
Revenue	86.3	101.8	123.3	101.0	64.0	73.2	77.8	67.3	82.5	111.5	122.6	117.3	110.1
Operating profit	3.8	7.5	6.2	1.8	-1.8	4.0	3.9	5.0	11.0	16.5	17.0	17.8	19.6
Operating margin	4.4%	7.4%	5.1%	1.8%	-2.8%	5.4%	5.1%	7.4%	13.4%	14.8%	13.9%	15.1%	17.8%
Other income	—	0.8	—	—	—	—	1.1	0.7	0.3	1.9	3.7	1.9	0.8
Interest	1.4	1.4	1.8	2.0	2.6	2.9	2.8	3.1	3.0	2.4	0.9	—	1.1
Depreciation	1.0	1.2	1.4	1.5	1.6	1.6	2.1	1.9	1.9	2.1	2.2	2.5	2.5
Profit before tax	1.8	5.6	4.5	-0.7	-4.9	0.2	0.1	0.7	6.4	13.7	17.5	16.6	16.8
Tax	0.4	1.7	1.5	0.2	0.1	0.1	-0.3	0.2	1.2	3.8	5.5	4.3	4.3
Net profit	1.4	4.0	3.0	-0.8	-4.9	0.1	0.4	0.5	5.2	9.9	12.0	12.3	12.5

Quarters

showing latest 8 of 56 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†	JUN '19†	SEP '19†	DEC '19†	MAR '20†	JUN '20†	SEP '20†	DEC '20†	MAR '21†	JUN '21†
Revenue	20.3	13.3	26.3	13.0	26.1	27.9	19.3	23.3	21.1	29.6	27.8	18.4	28.0	32.4	44.5	23.5	25.3	20.4	31.8	11.0	22.3	12.1	18.5	18.5	20.4	12.0	22.4	19.0	27.3	12.9	18.6	17.2	17.9	14.1	18.0	17.2	22.9	20.0	22.3	26.0	27.9	28.3	29.3	32.8	32.5	24.1	33.3	31.1	35.5	35.3	15.4	26.1	30.8	32.9	20.3	27.5
Operating profit	0.9	0.9	1.3	0.4	1.4	2.1	-0.1	1.4	1.7	2.3	2.1	1.3	1.2	2.5	1.3	-0.7	-0.9	-0.0	3.5	-0.4	-0.1	-0.8	-0.5	1.2	1.9	0.5	0.3	0.9	1.7	0.4	1.0	0.7	1.2	-0.4	3.4	2.3	2.7	2.7	3.3	4.1	3.7	4.9	3.8	4.2	4.1	4.4	4.3	5.0	5.7	5.4	1.6	3.9	5.5	5.2	4.9	6.0
Operating margin	4.4%	6.5%	5.0%	2.9%	5.5%	7.6%	-0.7%	5.9%	8.1%	7.8%	7.6%	7.0%	4.2%	7.7%	2.8%	-2.8%	-3.7%	-0.1%	10.9%	-3.7%	-0.5%	-6.4%	-2.8%	6.7%	9.4%	4.4%	1.3%	4.6%	6.2%	3.2%	5.2%	4.2%	6.9%	-2.8%	19.1%	13.3%	11.9%	13.7%	14.6%	15.6%	13.3%	17.4%	12.9%	12.9%	12.7%	18.2%	12.9%	16.1%	16.0%	15.4%	10.5%	14.9%	18.0%	15.9%	24.0%	21.9%
Other income	0.1	0.2	0.1	0.3	—	0.0	0.1	0.2	0.4	0.1	0.1	0.2	—	0.4	0.8	0.2	0.8	—	0.0	0.7	—	0.2	0.3	0.2	—	0.1	0.4	0.5	0.2	0.3	0.1	0.2	0.3	0.1	0.1	0.3	0.0	0.3	-0.3	0.3	0.8	-0.2	1.0	1.2	1.8	0.1	0.6	0.0	0.3	0.5	1.1	0.1	0.1	0.0	0.5	0.1
Interest	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.2	0.3	0.6	0.4	0.5	0.5	0.5	0.4	0.5	0.5	0.7	0.6	0.7	0.6	0.7	0.6	0.8	0.7	0.8	0.6	0.7	0.7	0.8	0.8	0.8	0.7	0.8	0.7	0.8	0.7	0.9	0.5	0.6	0.7	0.5	0.4	0.3	0.2	0.0	0.2	0.2	0.2	—	0.2	0.4	0.1	0.4	0.0
Depreciation	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.5	0.6	0.7	0.6	0.6	0.6	0.7	0.7	0.7	0.7	0.4	1.3
Profit before tax	0.3	0.5	0.8	0.1	0.8	1.5	-0.6	1.0	1.5	1.8	1.3	0.8	0.4	2.0	1.3	-1.2	-1.0	-0.9	2.5	-0.7	-1.2	-1.6	-1.3	0.5	0.7	-0.5	-0.5	0.2	0.6	-0.4	-0.2	-0.3	0.3	-1.5	2.2	1.4	1.4	1.9	1.6	3.1	3.4	3.4	3.8	4.5	5.1	3.7	4.2	4.3	5.2	5.1	2.0	3.0	4.6	4.5	4.6	4.8
Tax	0.1	0.1	0.2	0.0	0.1	0.2	-0.0	0.3	0.3	0.7	0.4	0.3	0.1	0.7	0.4	0.0	0.1	0.0	0.1	0.1	0.0	0.0	-0.0	0.0	0.2	-0.1	-0.1	-0.1	0.1	-0.1	-0.2	-0.0	-0.0	-0.1	0.3	0.3	0.3	0.2	0.4	0.6	0.7	0.6	1.9	1.3	1.6	1.2	1.4	1.0	1.4	1.4	0.6	0.9	1.4	1.4	0.5	0.6
Net profit	0.3	0.4	0.6	0.0	0.7	1.3	-0.6	0.7	1.2	1.1	0.9	0.5	0.3	1.4	0.9	-1.2	-1.1	-0.9	2.4	-0.8	-1.2	-1.7	-1.3	0.5	0.5	-0.4	-0.4	0.3	0.5	-0.4	0.0	-0.2	0.3	-1.5	1.8	1.1	1.1	1.7	1.1	2.5	2.7	2.8	1.9	3.2	3.6	2.4	2.8	3.3	3.8	3.7	1.5	2.1	3.2	3.0	4.1	4.2
EPS ₹	0.37	0.50	0.79	0.03	0.90	1.64	-0.78	0.87	1.59	1.47	1.17	0.68	0.35	1.76	1.13	-1.58	-1.33	-1.21	3.09	-0.96	-1.46	-2.02	-1.51	0.54	0.60	-0.50	-0.52	0.34	0.56	-0.41	0.01	-0.26	0.39	-1.47	1.83	1.14	1.16	1.66	1.10	2.28	2.42	2.49	1.66	2.75	3.05	2.06	2.43	2.75	3.18	3.05	1.20	1.72	2.64	2.47	3.39	3.40
Revenue YoY	—	—	—	—	28.8%	109.3%	-26.5%	78.4%	-19.2%	6.2%	44.0%	-21.0%	32.9%	9.4%	59.9%	28.0%	-9.6%	-37.1%	-28.6%	-53.1%	-11.9%	-40.6%	-41.6%	67.2%	-8.7%	-0.7%	20.8%	3.0%	34.1%	7.2%	-17.1%	-9.4%	-34.3%	9.5%	-3.2%	0.1%	27.6%	41.8%	23.9%	50.8%	21.9%	41.3%	31.5%	26.0%	16.4%	-14.9%	13.5%	-5.0%	9.3%	46.8%	-53.8%	-16.1%	-13.4%	-6.8%	32.4%	5.4%
Profit YoY	—	—	—	—	150.0%	223.1%	-198.4%	3300.0%	75.7%	-9.5%	—	-22.1%	-78.0%	19.3%	-4.4%	-335.8%	-488.9%	-169.9%	180.5%	—	—	—	-152.0%	—	—	—	—	-33.3%	-2.0%	—	—	-176.7%	-30.0%	—	18100.0%	—	228.6%	—	-36.8%	122.1%	133.0%	64.2%	61.7%	28.3%	32.8%	-15.1%	52.7%	1.9%	7.9%	52.7%	-48.6%	-36.0%	-16.1%	-18.2%	183.6%	97.6%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 13 periods

	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '26	JUN '26
ROE	—	5.9%	5.9%	7.7%	7.9%	6.6%	4.7%	3.8%	2.5%	2.3%	3.6%	3.9%	3.9%
ROCE	—	9.0%	8.7%	9.2%	9.4%	8.4%	7.9%	7.6%	6.1%	5.8%	6.1%	4.8%	4.8%
Net margin	9.6%	9.0%	8.8%	10.5%	10.2%	8.2%	5.5%	4.2%	2.8%	2.7%	4.4%	5.5%	5.3%
EBITDA margin	19.1%	18.7%	17.9%	17.0%	16.8%	15.0%	13.5%	12.4%	10.4%	10.7%	11.8%	9.9%	9.5%
Debt / equity	—	0.15	0.15	0.13	0.13	0.15	0.15	0.15	0.15	0.09	0.09	0.17	0.17
Interest coverage	9.34	7.87	7.05	6.82	6.58	5.61	5.37	3.96	3.39	3.20	3.29	4.43	4.92
Asset turnover	—	0.47	0.48	0.51	0.54	0.54	0.57	0.61	0.61	0.63	0.62	0.53	0.54

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 7 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	SEP '25	MAR '26
Share capital	12.7	12.7	12.7	12.7	12.7	13.6	13.6
Other equity / reserves	173.2	180.8	187.2	187.8	203.2	261.9	262.0
Total equity	185.8	193.4	199.9	200.5	215.9	275.4	275.6
Borrowings	28.5	24.2	29.0	30.8	20.2	38.6	47.8
Current liabilities	70.0	82.6	94.1	91.0	68.8	85.6	87.9
Non-current liabilities	2.9	2.5	3.4	3.0	3.8	6.1	8.5
Total assets	258.7	278.5	297.4	294.5	288.5	367.1	372.0
Property, plant & equipment	92.5	91.8	92.2	91.0	87.8	85.0	84.1
Capital work-in-progress	—	—	0.8	—	—	—	—
Investments	0.0	0.0	0.0	0.0	0.0	8.1	0.0
Inventories	28.9	45.1	56.3	59.4	60.0	68.8	70.1
Receivables	67.3	65.3	74.8	55.3	56.6	77.6	81.8
Cash & equivalents	30.6	20.8	13.4	14.8	6.4	43.7	31.3

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY26
Cash from operations	4.1	-6.3	-0.4	-33.2
Cash from investing	-8.5	-5.9	-5.6	-3.0
Cash from financing	4.3	29.1	-0.1	63.7
Capex	8.6	6.6	6.3	4.8
Free cash flow	-4.5	-12.9	-6.7	-38.0
Dividends paid	1.2	1.3	1.3	1.4

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹84.1 cr23%

Inventories

₹70.1 cr19%

Receivables

₹81.8 cr22%

Cash & equivalents

₹31.3 cr8%

Other assets

₹104.7 cr28%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Medicamen Biotech Limited	374	275.70	34.5	1.36	3.9%

StoxGud checklist: Neutral setup · 5/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-12.0%

6 months-6.3%

1 year-22.1%

3Y CAGR-25.6%

5Y CAGR-16.8%

10Y CAGR—

50-day avg₹289.08

200-day avg₹275.29

RSI (14)45

FAQs

What is the share price of Medicamen Biotech Limited?

Medicamen Biotech Limited (MEDICAMEQ) closed at ₹275.70 on NSE on 06 Nov 2026.

What is the market cap of Medicamen Biotech Limited?

₹374 crore at the latest close.

What is the P/E ratio of Medicamen Biotech Limited?

34.5, on trailing-twelve-month earnings from its filings.

How fast is Medicamen Biotech Limited growing?

Medicamen Biotech Limited: revenue has compounded at 19.7% a year over three years. Latest-quarter revenue is up 11.3% year on year, profit down 1.4%.

How profitable is Medicamen Biotech Limited?

On a trailing-twelve-month basis return on equity is 3.9%, return on capital employed 4.8%, operating margin 9.5%, net margin 5.3%.

How much debt does Medicamen Biotech Limited have?

Medicamen Biotech Limited is lightly geared: debt to equity is 0.17 with borrowings of ₹48 cr against cash of ₹31 cr (balance sheet of 2026-03-31). Operating profit covers interest 4.9 times.

Financials parsed from Medicamen Biotech Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from SEP '21, annual from FY22, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.